Back to Search
Start Over
Intramyocardial, autologous CD34+ cell therapy for refractory angina.
- Source :
-
Circulation research [Circ Res] 2011 Aug 05; Vol. 109 (4), pp. 428-36. Date of Electronic Publication: 2011 Jul 07. - Publication Year :
- 2011
-
Abstract
- Rationale: A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function.<br />Objective: Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options.<br />Methods and Results: In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1×10(5) or 5×10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8±1.1 versus 10.9±1.2, P=0.020) and 12 months (6.3±1.2 versus 11.0±1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139±151 versus 69±122 seconds, P=0.014; 12 months: 140±171 versus 58±146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients.<br />Conclusions: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies.
- Subjects :
- Aged
Angina Pectoris etiology
Angina Pectoris mortality
Angina Pectoris pathology
Angina Pectoris physiopathology
Biomarkers metabolism
Blood Component Removal
Cardiovascular Agents therapeutic use
Double-Blind Method
Endothelial Cells immunology
Exercise Test
Exercise Tolerance
Female
Hematopoietic Stem Cell Mobilization
Humans
Least-Squares Analysis
Male
Middle Aged
Myocardial Ischemia complications
Myocardial Ischemia mortality
Myocardial Ischemia pathology
Myocardial Ischemia physiopathology
Neovascularization, Physiologic
Prospective Studies
Regeneration
Regression Analysis
Risk Assessment
Risk Factors
Surveys and Questionnaires
Time Factors
Tomography, Emission-Computed, Single-Photon
Transplantation, Autologous
Treatment Outcome
United States
Angina Pectoris surgery
Antigens, CD34 metabolism
Coronary Circulation
Endothelial Cells transplantation
Hematopoietic Stem Cell Transplantation adverse effects
Microcirculation
Myocardial Ischemia surgery
Myocardium pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4571
- Volume :
- 109
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Circulation research
- Publication Type :
- Academic Journal
- Accession number :
- 21737787
- Full Text :
- https://doi.org/10.1161/CIRCRESAHA.111.245993